Autopsy report · NCT00654433

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases

“Terminated - Sponsor Decision”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 8 months before it stopped.
• 40 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Aldagen

Sponsor type

Industry

Conditions

Inherited Metabolic Diseases; Lysosomal Storage Disorders; Peroxisomal Storage Diseases; Inborn Errors of Metabolism; Mucopolysaccharidosis

Interventions

ALD-101

Participants

40 (planned, not actual)

Sites

3

Countries

United States

Trials that died the same way

• Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
  “Terminated by previous Sponsor decision” (96% match in meaning)
• A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
  “Terminated by Sponsor” (91% match in meaning)
• RibFix Advantage™ Post-Market Follow-Up
  “Sponsor Terminated” (90% match in meaning)
• Evaluation of Cranioplasty Using Native Bone Autograft Versus Synthetic Bone Allograft
  “Sponsor termination” (90% match in meaning)
• Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
  “Sponsor requested termination” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.